Background. Previous evidence of race disparities in smoking cessation treatment has been limited to mostly survey studies which increase the potential for recall bias. We examined if African American versus white patients in primary care are less likely to receive any treatment or if race disparities are specific to the type of treatment offered using data pulled from a large electronic health record system. Methods. Medical record data from 3510 white and 2707 African American patients were available from primary care encounters between 2008 and 2015 and was used to define smoking status, cessation treatments (counselling and medication), and covariates. The association between race and type of smoking cessation treatment offered was measured by logistic regression models before and after adjusting for covariates. Results. Smoking cessation counselling was offered to 9.3% of African American and 7.8% of white patients, and a prescription for smoking cessation medication was offered to 12.3% of African American and 16.4% of white patients. After adjusting for covariates in logistic regression models, whites were significantly less likely than African American patients to receive smoking cessation counselling [odds ratio (OR) = 0.81; 95% confidence interval (CI) = 0.65-0.99] and were significantly more likely to receive a prescription for a smoking cessation medication (OR = 1.23; 95% CI = 1.03-1.47). Conclusions. Less than 20% of smokers received any type of therapy to assist in smoking cessation. We observed a race disparity in type of smoking cessation therapy provided to white and African American primary care patients. Further research is needed to increase treatment rates and eliminate disparities.
Introduction
Tobacco use is the leading preventable cause of death and disease in the United States (1, 2) . In the United States alone, more than 480 000 deaths per year can be attributed to cigarette smoking (2) . The deaths caused by smoking outnumber the deaths caused by the human immunodeficiency virus, illegal drug use, alcohol use, motor vehicle injuries, and firearm-related injuries combined (3) .
Since the Surgeon General's report on smoking and health in 1964, cigarette smoking has declined, yet disparities in tobacco use among racial and ethnic minorities continue to exist (4, 5) .
In 2014, current cigarette smoking was highest among non-Hispanic American Indians/Alaska Natives and people of multiple races. Nearly 18 of every 100 non-Hispanic African Americans (African American; 17.5%) were current smokers (6) . However, smoking disparities are not limited by smoking status alone but also include noted differences in smoking cessation. Per a 2017 CDC report for 2015 data, only 57.2% of smokers had been advised by a health professional to quit and only 31.2% used cessation counselling and/or medication when attempting to quit (7) .
Compared to whites, African Americans are less likely to be successful with smoking cessation despite lower consumption, greater motivation and readiness to quit (8) , and more confidence that they will be successful in their quit attempt (9) . Potential contributors to less successful cessation among African American patients may be due to lower rates of screening for nicotine use and lower odds of receiving cessation advice and evidence-based treatments to aid in cessation (10) (11) (12) (13) .
While race disparities have been demonstrated in receipt of any type of cessation aid, with few exceptions (13, 14) , much of this research has been based on self-report data. Trinidad et al. (10) found no race disparity from a 2003 nationally representative survey of US adults which revealed 57.4% of African Americans and 59.8% of whites reported receiving advice from a health professional to stop smoking and equally low numbers of both races (12.7% African American and 15.9% white) reported receiving a prescription for nicotine replacement or antidepressant to aid smoking cessation. In contrast, analysis of the 2000 Behavioral Risk Factor Surveillance Study indicated African Americans were significantly less likely than whites to report being told to quit by a health professional to quit smoking (61.0% versus 72.0%) (11) .
Existing studies of race disparities in smoking cessation treatment using medical record data are inconsistent. There was no evidence of race disparities in provision of smoking cessation treatment for Veterans Health Administration (VA) patients with coronary artery disease in 1999 to 2000 (13) ; however, more recent analysis of VA medical record data (2005-12) revealed just 17.5% of patients received nicotine replacement therapy (NRT) or medication for smoking cessation within 48 hours following hospital discharge for chronic obstructive pulmonary disease and African American patients were significantly less likely (OR = 0.34; 95% CI = 0.12-0.97) than white patients to receive treatment (14) . These existing studies using medical record data are inconsistent, have relied on clinical data from patients with smoking related disease and have not focused on primary care encounters. To our knowledge, no existing studies have determined if race disparities exist in the type of smoking cessation support provided to white versus African American patients in primary care as measured from electronic medical record (EMR) data generated during real world medical encounters.
To address this gap, we used a large medical record cohort to determine if race disparities exist in the type of smoking cessation treatment provided to African Americans versus whites. Specifically, we determined if white and African American patients differed in the odds of receiving counselling to stop smoking or a prescription for a smoking cessation medication. We hypothesized that African American patients, compared to white patients, would be less likely to receive any type of smoking cessation treatment during primary care encounters.
Methods

Subjects
Data were obtained from the Department of Family and Community Medicine's Primary Care Patient Data Registry (PCPD). The PCPD contains data from clinic visits to any of three academic family medicine clinics and three general internal medicine clinics. These primary care clinics are distributed in both the urban and suburban St Louis metropolitan area. Ambulatory clinic visits from 33 661 patients in the PCPD occurred between 1 July 2008 and 30 June 2015. Clinic data were extracted from EPIC electronic medical records to obtain ICD-9-CM codes, prescription orders, CPT codes, social history, family history, demographics, laboratory orders, referrals and vital signs. The creation of this retrospective cohort and its use for primary care research was approved by the Institutional Review Board. Additional PCPD details have been previously reported (15) (16) (17) (18) .
Eligibility for the present study required patients to be 18 years of age or older (n = 31 569) and current smokers (n = 6451) as documented in the patient social history or by ICD-9-CM code for nicotine dependence. Patients were limited to white or African American race, reducing the sample to 6233. After limiting to those patients with complete demographic data, the final analytic study sample size was 6217.
Study design
The entire observation period (2008-15) was treated as a crosssection. Race was the predictor variable and the two outcome measures were medical record documented receipt of smoking cessation counselling and prescription for a smoking cessation medication (i.e. buproprion and varenicline). Smoking cessation counselling was identified by an EMR flag and could indicate either brief counselling by the primary care provider and/or referral to counselling for smoking cessation by a smoking cessation counsellor. Brief counselling by the primary care provider typically consists of health information outlining the deleterious effects of smoking such as cardiovascular disease, pulmonary disorders, and cancer. While it is likely that some discussion of the benefits of smoking cessation accompanied initiating a prescription, this was not considered cessation counselling unless the EMR contained the counselling flag.
Covariates included socio-demographics, volume of health services utilization, comorbid psychiatric and substance use disorders and chronic health conditions. We adjusted for age, gender and neighbourhood socieconomic status (SES) (nSES: high versus low) because smoking status is associated with younger age, male gender (19, 20) and lower nSES (19) (20) (21) . nSES has been described elsewhere (22) and accounts for zip code level census estimates of percent of households below poverty, receiving public assistance, and with income below $35 000 as well as percent of adult males in the labour force, percent of adults with less than a high school education, median household income and median value of single family homes. To adjust for detection bias, we included a covariate measuring volume of health care utilization that was computed from the average number of clinic visits per month. The distribution was divided into quartiles. A binary health care use variable was used in analysis and defined by the highest quartile of health care use versus all other levels.
Using ICD-9-CM codes, we computed variables describing diagnoses for depression and any anxiety disorder, which was a composite of any of the following: anxiety disorder unspecified, generalized anxiety disorder, panic disorder, obsessive compulsive disorder, social phobia and post-traumatic stress disorders. The occurrence of two ICD-9-CM codes within any 12-month period had to occur for a positive anxiety or depression diagnosis (23) . Substance use disorder was defined by any ICD-9-CM code for alcohol or drug abuse/dependence. ICD-9-CM codes were used to define the presence of diabetes, hypertension, hyperlipidemia and vascular disease, which was a composite of cerebrovascular and cardiovascular disease. Obesity was defined by body mass index of 30.0 kg/m 2 or above, and/or an ICD-9-CM diagnosis (278.00).
Analytic approach
All analyses were conducted at a two-tailed alpha of 0.05 using SAS v9.4. The distributions of covariates and outcomes were compared between white (n = 3510) and African American (n = 2707) patients using chi-square tests for categorical variables and independent samples t-tests for continuous variables. Similarly, covariate distributions were compared among each level of both outcomes (e.g. smoking cessation counselling and prescription for smoking cessation medication) using chi-square and t-tests. Separate logistic regression models described the relationship of race and each outcome before and after adjusting for covariates using odds ratios (ORs) and 95% confidence intervals (CIs).
Results
As shown in Table 1 , the sample was on average 49.5 (95% CI = 49.2-49.9) years of age, approximately half were female (53.5%) and 38.4% had a high nSES. Overall, 14.6% and 8.5% of adult smokers were offered a smoking cessation prescription or smoking counselling, respectively. African American patients were more likely than whites to receive counselling (9.3% versus 7.8%, χ 2 (1) = 4.5, P = 0.035); and white patients were more likely than African American patients to receive smoking cessation prescriptions (16.4% versus 12.3%, χ 2 (1) = 20.7, P < 0.0001). Compared to white patients, African American patients were significantly older, more often female, had lower nSES, and higher health care utilization than whites. African American patients were significantly less likely than whites to have been diagnosed with depression and anxiety disorder, and more likely to have any substance use disorder. Obesity and all chronic health conditions were significantly more prevalent in African American than white patients.
Associations between covariates and receipt of smoking cessation counselling are shown in Table 2 . Compared to patients receiving no smoking counselling, those receiving any smoking counselling were significantly more often high clinic utilizers, diagnosed with depression, obese, and diagnosed with hyperlipidemia. No other variables were significantly associated with receipt of smoking counselling.
Associations between covariates and receipt of a prescription for a smoking cessation medication are shown in Table 3 . Patients that received a prescription for a smoking cessation medication were significantly more often female, had a higher nSES, and had more health care utilization. Diagnoses for depression, anxiety, and substance use disorder were all significantly more prevalent among patients who received a smoking cessation prescription. Obesity and all chronic physical disease measures, with the exception of vascular disease, were significantly more prevalent among those who received smoking cessation medication.
Results of unadjusted and adjusted logistic regression models are presented in Table 4 . Before and after adjusting for covariates, whites were significantly less likely than African American to receive smoking cessation counselling (unadjusted OR = 0.82; 95% CI = 0.65-0.99; adjusted OR = 0.81; 95% CI = 0.65-0.99). In the multivariate model, covariates significantly associated with greater odds of receiving smoking cessation counselling included high health care utilization, depression and obesity. Vascular disease was associated with lower odds of smoking cessation counselling.
Before adjusting for covariates, compared to African American, whites had a 40% (OR = 1.40; 95% CI = 1.21-1.62) increased odds of receiving a prescription for smoking cessation medication. This association remained significant after adjusting for covariates (OR = 1.23; 95% CI = 1.03-1.47). Covariates associated with greater odds of receiving smoking cessation medication included high nSES, high clinic utilization, depression, anxiety, substance use disorder, obesity and hyperlipidemia.
Discussion
In a large cohort of 6217 primary care patients who were current smokers between 2008 and 2015, we observed differences by race in receipt of smoking cessation counselling and prescription of medication for smoking cessation. After adjusting for covariates, white patients compared to African American patients were significantly Bolded text indicates significant confidence intervals (P < 0.05). from studies which ask patients if a physician ever advised them to stop smoking (10, 11) . Lifetime self-reported advice to quit smoking is much broader construct and lower intensity treatment than counselling or prescription medication. Our findings are consistent and out-perform the 12.7% of African Americans and 15.9% of whites who reported ever receiving a prescription to stop smoking in a 2003 survey (10) . Low rates of treatment for smoking cessation are a large gap in health care quality. Several suggestions for bridging the 'quality chasm' (24) are suited for providing smoking cessation treatment. Increasing access by internet and phone encounters could be used to help patients initiate NRT, anticipating needs could help clinicians intervene when patients are motivated to quit smoking, e.g. after an acute smoking related infection such as bronchitis, and sharing knowledge and evidence and transparency (24,25) could set reasonable expectations for smoking cessation treatments. Patients should be aware that they need to maintain motivation to quit smoking and understand that available treatments are aids to help persons quit and do not remove all craving and withdrawal. While electronic health records (EHR) have improved delivery of smoking cessation interventions (26), the present study was conducted in an era of clinical reminders and low rates of smoking cessation treatment provided at hospital discharge in the VA, a system which has led the United States in EHR clinical reminders, demonstrates technology alone is not sufficient to cross the quality gap (14) . Quality improvement for smoking cessation treatment may be achieved with a multi-prong approach. For example involving a physician champion, physician and practice-level assessments and feedback and rapid-cycle quality improvement training has been shown to increase delivery of preventive care, including tobacco use counselling (27) .
Studies that compared receipt of treatment for smoking cessation in medical record data found no differences in therapy provided to white and African American patients (13, 14) . However, one was limited to patients with cardiovascular disease and the urgent need to stop smoking in this population may have reduced potential race disparities. Solberg et al.'s(28) analysis of medical group data revealed the prevalence of receiving and filling a medication for smoking cessation was similar in white and African American patients but significantly lower among Hispanic/Latino, multi-ethnic and Asian patients. However, direct comparisons to our findings are difficult because this study did not exclude patients with unknown race and was not limited to primary care encounters.
Previous survey studies reveal whites are more likely than African American to receive counselling, NRT and pharmacotherapy for smoking cessation (5), (29), (30) . Our study demonstrated that whites receive more smoking cessation medication prescriptions and African American receive more counselling for smoking cessation. Some evidence suggests receipt of therapy for smoking cessation may be patient driven. African American in Ryan et al.'s (29) study reported distrust of pharmacotherapy effectiveness, concerns about addiction to medication, and belief that medication was not necessary to quit smoking.
Because psychiatric disorders were all more prevalent among white race, it is possible that medication was more often prescribed to these patients given substantial evidence that ability to stop smoking is inversely associated with depression, anxiety and substance use disorders (31, 32) . Despite significantly higher prevalence of obesity, diabetes, hypertension, hyperlipidemia and vascular disease among African American patients, these conditions did not change the association between race and type of smoking treatment provided. This raises a concern that patients most in need of cessation are not receiving aggressive treatment, i.e. a combination of therapy and medication.
In adjusted models, hyperlipidemia was significantly associated with prescription of smoking cessation medication. This highlights one weakness of our study which is the cross-sectional design which prevents us from determining if covariates preceded or occurred after patients received treatment for smoking cessation. Thus, the unusual finding that patients with comorbidities made worse by smoking may not have had the condition at the time smoking cessation was offered. The results of this study were limited to academic family medicine and general internal medicine in Missouri which has a higher level of smoking than many other regions of the United States. We found 20% of our patient population were current smokers which is consistent with Centers for Disease Control 2016 State of Missouri prevalence estimates (20-23.7%) for current smoking (https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/ cig_smoking/index.htm). It is not known if similar results would be found in private practice settings, other regions of the United States, or other parts of the world. Last, available data began in 2008 and it is possible that patients were given medication or counselling before the start of this time period and patient experiences with past counselling or medication could influence provider treatment choice during this period of observation.
This study only included counselling if it had been documented utilizing a best practice advisory alert within the EMR. If the patient was referred to an outside source and a referral code was not generated within the EMR, that data were not included. This study also did not incorporate types of insurance as a variable because encounter billing information is stored in a separate system. Coverage for medications vary and this may have negatively contributed to who received prescriptions. These limitations could bias our results if any these factors, (e.g. insurance data) are correlated with race and type of treatment received.
Use of NRT products could have influenced our results. Medicaid covers the cost of NRT and prescriptions for NRT can be written for this group of patients. Including NRT prescription written by our physicians would introduce poverty as a confound in estimates of race disparities and prescribed smoking cessation treatment. To inform interpretation of our results we conducted post hoc analysis by measuring the association between NRT from any of the following sources: patient self-reported medication list which includes over the counter and prescription NRT by physicians outside our system and NRT prescriptions by our physicians for patients receiving Medicaid. In the study cohort (n = 6217) we observed 6.8% received NRT either prescribed or obtained by purchasing NRT over the counter. Among African Americans, 10.2% had NRT versus 4.2% in whites (P < 0.0001). Combining NRT with prescriptions for smoking cessation medication results in 19.5% of African Americans and 18.9% of whites receiving some type of non-counselling treatment. This unadjusted comparison indicates no race difference in pharmacological treatment for smoking cessation. It is possible that the higher prevalence of NRT among African American patients partly explains the lower prevalence of prescriptions for smoking cessation medications in African American versus white patients.
Conclusions
Though previous studies have demonstrated disparities in smoking cessation treatments in minority groups, most have utilized surveys which rely on recall and therefore potential recall bias. This study used data from EMR and demonstrated a disparity among African
